Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of NoNO-42 in healthy adults
NCT05636306Phase 1Completed
- Sponsor
- NoNO Inc.
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing NoNO-42 with Placebo (2 arms). Primary endpoint: Frequency of Adverse Events, abnormal laboratory findings and abnormal vital signs at 28 days. Started Nov 2022; status: completed.
02
Drugs
NoNO-42
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05636306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636306.